Tango Therapeutics(TNGX) - 2025 Q3 - Quarterly Results

Vopimetostat Efficacy and Response Rates - Vopimetostat demonstrates an overall response rate (ORR) of 27% across multiple cancer types, with a median progression-free survival (mPFS) of 7.2 months in 2L MTAP-del pancreatic cancer[11][30][35] - In the histology agnostic cohort, Vopimetostat achieved a 49% ORR and mPFS of 9.1 months, supporting its potential as a best-in-class treatment[11] - Vopimetostat achieved a 49% overall response rate (ORR) in the histology agnostic cohort with a median progression-free survival (mPFS) of 9.1 months[47][50] - The drug demonstrated a strong activity across cancer types, with an ORR of 27% and mPFS of 6.4 months for all histologies, and 25% ORR with 7.2 months mPFS in 2L pancreatic cancer[54] - The median time to RECIST response for Vopimetostat is 3.5 months, indicating a relatively quick onset of efficacy[13] Clinical Trials and Future Studies - The pivotal study for Vopimetostat in 2L pancreatic cancer is planned to start in 2026, targeting 150 patients with MTAP deletion[37][38] - The company anticipates rapid enrollment of ~300 patients for the pivotal study due to high unmet medical need in the target population[38] - Vopimetostat's pivotal trial design is expected to be finalized in an upcoming FDA interaction, focusing on MTAP-del patients[38] - The ongoing combination study of Vopimetostat with RAS inhibitors shows robust enrollment and plans to expand to first-line cohorts[11][40] - The ongoing study has the potential to support a first-line pivotal study with shorter timelines than competitors[43] - Ongoing combination studies of Vopimetostat with daraxonrasib or zoldonrasib may provide a pathway to first-line registration in pancreatic and lung cancer[54] - Enrollment for the Vopimetostat lung cancer cohort is fully completed with 41 patients, and an update is planned for 2026[44] Patient Population and Safety Profile - The patient population for Vopimetostat development includes approximately 60,000 patients per year in the US, with key indications in pancreatic cancer (~20,000 patients/year) and lung cancer (~22,000 patients/year)[5] - Vopimetostat has a favorable safety profile, with 0% discontinuation due to drug-related events and only 8% of patients requiring dose reduction[25][22] - The median follow-up for tumor evaluable patients was 9.5 months, with 21 out of 37 patients ongoing[50] - Vopimetostat has shown durable activity in multiple lines of difficult-to-treat cancers, providing further evidence of single-agent activity[53] Dosage and Administration - The FDA has aligned on a 250 mg QD go-forward dose for Vopimetostat[54]